Back to top

oncology-screening: Archive

Zacks Equity Research

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.

ARCTPositive Net Change GLPGPositive Net Change FULCPositive Net Change BVSPositive Net Change

Zacks Equity Research

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.

ILMNPositive Net Change ARCTPositive Net Change ABBVPositive Net Change GMABPositive Net Change

Zacks Equity Research

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.

AZNPositive Net Change MRKPositive Net Change IMTXNo Net Change TRDAPositive Net Change

Zacks Equity Research

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.

ABBVPositive Net Change SYRSPositive Net Change IMTXNo Net Change TRDAPositive Net Change